532 Objectives: There is great scientific and clinical interest in alpha particle emitting
radiotherapies because of their potent antineoplastic effects and normal-tissue sparing …

Rationale: Alpha particle emitting radiopharmaceuticals are generating considerable
interest for the treatment of disseminated metastatic disease. Molecular imaging of the …

Thorium-227-based alpha-particle radiopharmaceutical therapies ({\alpha}-RPTs) are being
investigated in several clinical and pre-clinical studies. After administration, Thorium-227 …

In preparation for an α-particle therapy trial using 1–7 MBq of 224Ra, the feasibility of
tomographic SPECT/CT imaging was of interest. The nuclide decays in 6 steps to stable …

P1331 Introduction: An important need exists for methods to quantify absorbed dose in
lesions and radiosensitive organs in alpha-particle radiopharmaceutical therapy (a-RPT) 1 …

Purpose Alpha-particle emitting radiopharmaceutical therapy (αRPT) is emerging as a
highly potent treatment for metastatic cancer. Actinium-225 has a half-life of 10 days and a …

2399 Introduction: 227 Th-labelled conjugates are an emerging class of α-particle
radiopharmaceutical therapies (α-RPTs)[1-3]. 227 Th decays to 223 Ra, another α-particle …

Objective. The development of alpha-emitting radiopharmaceuticals using 225 Ac (t ½= 9.92
d) benefits from the quantitative determination of its biodistribution and is not always easy to …

Attaching alpha-emitting radionuclides to cancer-targeting agents increases the anti-tumor
effects of targeted cancer therapies. The success of alpha therapy for treating bone …

Despite ongoing efforts with new chemotherapeutics, small-molecule inhibitors and
biologics, patients with distant metastases continue to have a grim prognosis …